한글목차

QUTENZA(8% 캡사이신)는 TRPV1 채널 작용제이며 처방 강도의 캡사이신을 함유하는 국소 시스템입니다. PHN)에 관련 신경 병증 통증 및 당뇨병 성 말초 신경 병증(DPN)과 관련된 발 신경 병증 통증의 치료제로 승인되었습니다. QUTENZA의 적응 확대를 계획하고 있습니다.

앞으로 몇 년동안 세계의 광범위한 조사와 의료비 증가로 수술 후 통증 시장 시나리오가 변할 것입니다. 개발, 과제 평가, QUTENZA의 이점에 그림자 울림을 줄 수있는 기회를 모색하고 있습니다. 수술 후 통증에 대한 다른 신흥 제품이 QUTENZA에 엄격한 시장 경쟁을 가져올 것으로 예상되며 가까운 미래에 후발 신흥 치료제가 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

이 보고서는 주요 7개국의 QUTENZA 시장을 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술후 통증에 있어서의 QUTENZA의 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 QUTENZA 시장 평가

• 수술 후 통증에서 QUTENZA 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"QUTENZA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about QUTENZA for Postoperative pain in the seven major markets. A detailed picture of the QUTENZA for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the QUTENZA for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the QUTENZA market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

QUTENZA (8% capsaicin) is a TRPV1 channel agonist, a topical system containing prescription-strength capsaicin. It is a non-opioid treatment that provides prolonged pain relief for several months. It is already approved in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. Additionally, the company is planning for a label extension of QUTENZA, particularly in the United States, to include the treatment of postsurgical neuropathic pain (PSNP).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the QUTENZA description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on QUTENZA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the QUTENZA research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around QUTENZA.
• The report contains forecasted sales of QUTENZA for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for QUTENZA in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

QUTENZA Analytical Perspective by DelveInsight

• In-depth QUTENZA Market Assessment

This report provides a detailed market assessment of QUTENZA for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• QUTENZA Clinical Assessment

The report provides the clinical trials information of QUTENZA for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence QUTENZA dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to QUTENZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of QUTENZA in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of QUTENZA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the QUTENZA in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of QUTENZA?
• What is the clinical trial status of the study related to QUTENZA in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the QUTENZA development?
• What are the key designations that have been granted to QUTENZA for Postoperative pain?
• What is the forecasted market scenario of QUTENZA for Postoperative pain?
• What are the forecasted sales of QUTENZA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to QUTENZA for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. QUTENZA Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. QUTENZA Market Assessment

• 5.1. Market Outlook of QUTENZA in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of QUTENZA in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of QUTENZA in the United States for Postoperative pain
  • 5.3.2. Market Size of QUTENZA in Germany for Postoperative pain
  • 5.3.3. Market Size of QUTENZA in France for Postoperative pain
  • 5.3.4. Market Size of QUTENZA in Italy for Postoperative pain
  • 5.3.5. Market Size of QUTENZA in Spain for Postoperative pain
  • 5.3.6. Market Size of QUTENZA in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of QUTENZA in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options